Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers.
Recombinant human growth hormone has revolutionized the management of children and adolescents with growth hormone deficiency and other growth disorders, but clinical and ethical controversies remain regarding diagnostic approach, optimal recombinant human growth hormone dose and duration, and expected outcomes. Management of pubertal and transitioning patients with growth hormone deficiency has also commanded increased attention. Recent clinical studies that demonstrate the positive health benefits of recombinant human growth hormone in children with cystic fibrosis, inflammatory bowel disease, and juvenile rheumatoid arthritis have not yet clarified issues about patient selection and appropriate long-term use. An understanding of current recombinant human growth hormone indications and controversies can facilitate patient evaluation and expedite referral for potential treatment. This review summarizes current indications for recombinant human growth hormone use, discusses clinical challenges, and provides recommendations for pediatricians caring for children who may be appropriate candidates for recombinant human growth hormone therapy.
Hardin
Dana S
DS
Ohio State University and Columbus Children's Hospital, Columbus, OH 43205, USA. hardind@pediatrics.ohio-state.edu
Kemp
Stephen F
SF
Allen
David B
DB
D000293:Adolescent; D001171:Arthritis, Juvenile / Q000188:drug therapy; D002648:Child; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy; D019382:Human Growth Hormone / Q000096:biosynthesis / Q000172:deficiency*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D010372:Pediatrics; D017410:Practice Guidelines as Topic; D011218:Prader-Willi Syndrome / Q000188:drug therapy; D011994:Recombinant Proteins / Q000009:adverse effects / Q000096:biosynthesis* / Q000627:therapeutic use*; D013997:Time Factors
D011994:Recombinant Proteins; D019382:Human Growth Hormone